Prevalence of Latent Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A South-East London Cohort Study

被引：0
作者：
Paine, Gabriel Wisenfeld [1 ]
Cox, Rosie [1 ]
Evans, Rosa [1 ]
Hudson, Jake [1 ]
Baker, Lucy [1 ]
Simpson, Thomas [1 ]
机构：
[1] Lewisham & Greenwich NHS Trust, Univ Hosp Lewisham, London, England
来源：
LUNG CANCER | 2025年 / 200卷
关键词：
D O I：
10.1016/j.lungcan.2025.108243
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
133
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Delayed and posttreatment immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors
    Jacob, Saya
    Fisch, Samantha
    Face, Carolyn
    Huppert, Laura
    Quandt, Zoe
    Quintal, Laura
    Melisko, Michelle
    Majure, Melanie
    Chien, Jo
    Blaes, Anne
    Rugo, Hope
    CANCER RESEARCH, 2024, 84 (09)
  • [42] Delayed immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors.
    Jacob, Saya
    Quandt, Zoe
    Melisko, Michelle E.
    Majure, Melanie
    Chien, Amy Jo
    Blaes, Anne Hudson
    Heditsian, Diane
    Esserman, Laura
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] Clinical features of immune checkpoint inhibitor-related pneumonitis in older patients with lung cancer receiving immune checkpoint inhibitors-based therapy: a retrospective study
    Jiafan Liu
    Dongmei Zhou
    Na Wu
    Jia Liu
    Xiaonan Wang
    BMC Geriatrics, 25 (1)
  • [44] Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors: Antibiotics immune checkpoint inhibitors in advanced NSCLC
    Schett, Anne
    Rothschild, Sacha I.
    Curioni-Fontecedro, Alessandra
    Kraehenbuehl, Stephan
    Frueh, Martin
    Schmid, S.
    Driessen, Christoph
    Joerger, Markus
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (01) : 121 - 131
  • [45] Active and latent tuberculosis infections in patients treated with immune checkpoint inhibitors in a non-endemic tuberculosis area
    Stroh, Gregory R.
    Peikert, Tobias
    Escalante, Patricio
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (11) : 3105 - 3111
  • [46] Presence of NAFLD in Patients Receiving Immune Checkpoint Inhibitors Significantly Increases the Prevalence of Immune Medicated Hepatotoxicity
    Hamid, Osama
    Eltelbany, Ahmed
    Mohammed, Abdul
    Asaad, Imad
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S546 - S546
  • [47] Active and latent tuberculosis infections in patients treated with immune checkpoint inhibitors in a non-endemic tuberculosis area
    Gregory R. Stroh
    Tobias Peikert
    Patricio Escalante
    Cancer Immunology, Immunotherapy, 2021, 70 : 3105 - 3111
  • [48] Is chemoprophylaxis necessary for all latent tuberculosis infection patients receiving IL-17 inhibitors? A cohort study
    Shu, Dan
    Zhang, Zhuying
    Zhou, Eray Yihui
    Ma, Xuzhu
    Zhao, Yi
    DERMATOLOGIC THERAPY, 2020, 33 (06)
  • [49] Prognostic effect of cachexia in patients with non-small cell lung cancer receiving immune checkpoint inhibitors
    Matsuo, Norikazu
    Azuma, Koichi
    Murotani, Kenta
    Murata, Daiki
    Matama, Goushi
    Kawahara, Akihiko
    Kojima, Takashi
    Tokito, Takaaki
    Hoshino, Tomoaki
    THORACIC CANCER, 2023, 14 (15) : 1362 - 1367
  • [50] Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors
    Chong, Curtis R.
    Park, Vivian J.
    Cohen, Bevin
    Postow, Michael A.
    Wolchok, Jedd D.
    Kamboj, Mini
    CLINICAL INFECTIOUS DISEASES, 2020, 70 (02) : 193 - 199
12345